Ekso Bionics Holdings, Inc. announced that it has secured exclusive U.S. distribution rights for MediTouch Inc.’s BalanceTutor™ rehabilitation system, a 4‑D perturbation treadmill that delivers controlled forward, backward, and side‑to‑side movements to train patients’ balance while a safety frame supports them. The partnership allows Ekso to offer a complementary therapy platform that can be used alongside its existing exoskeleton products in inpatient and outpatient physical rehabilitation settings.
The deal positions Ekso to enter the balance‑rehabilitation market, a segment estimated to grow at a compound annual growth rate of 8–10% over the next decade. By adding the BalanceTutor to its portfolio, Ekso can provide a more comprehensive suite of motion‑based therapies, potentially increasing device adoption and revenue streams in the U.S. market. The exclusive rights also give Ekso a competitive edge, as the BalanceTutor is the only known rehabilitation system that employs an advanced 4‑D perturbation patented treadmill, giving the company a unique product offering in a niche market.
Ekso’s financial performance in the third quarter of 2025 showed revenue of $4.2 million, up 2% year‑over‑year from $4.1 million in Q3 2024 and a 105% sequential increase from $2.1 million in Q2 2025. The company reported a net loss of $1.4 million in Q3 2025, an improvement from a $2.1 million loss in Q3 2024. The partnership is expected to add incremental sales and service revenue, helping to offset the company’s ongoing net losses and support its goal of achieving profitability as its product mix expands.
Following the announcement, Ekso’s stock surged approximately 20%, reflecting investor confidence in the strategic fit of the BalanceTutor with Ekso’s existing exoskeleton solutions. Analysts at HC Wainwright & Co. and Lake Street upgraded their ratings to “Buy,” citing the partnership’s potential to broaden Ekso’s market reach and diversify its revenue base.
CEO Scott Davis said, “The BalanceTutor is synergistic with our current go‑to‑market strategy by leveraging a common customer call point with a technology that is complementary to our enterprise health exoskeleton solutions.” He added that the exclusive distribution rights will enable Ekso to accelerate market penetration of the new system through its established distribution network and clinical relationships.
The partnership represents a strategic pivot for Ekso, moving beyond its core exoskeleton business into a complementary rehabilitation niche. While the company continues to face financial headwinds, the addition of the BalanceTutor could provide a new revenue stream and reduce reliance on a single product line, positioning Ekso for longer‑term growth in the expanding balance‑rehabilitation market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.